Cutera Announces FDA Clearance Of AviClear As A Long-term Treatment For Mild To Severe Acne
Portfolio Pulse from Benzinga Newsdesk
Cutera has announced FDA clearance for its AviClear treatment, a long-term solution for mild to severe acne. This approval will allow Cutera to market and sell AviClear in the United States.
June 15, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cutera's FDA clearance for AviClear treatment is expected to have a positive short-term impact on the company's stock price.
The FDA clearance for Cutera's AviClear treatment allows the company to market and sell the product in the United States. This is likely to increase revenues and have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100